Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center

被引:11
|
作者
Mikus, Mislav [1 ]
Benco, Nikolina [2 ]
Matak, Luka [3 ]
Planinic, Pavao [1 ]
Coric, Mario [1 ]
Lovric, Helena [1 ]
Radosevic, Velena [1 ]
Puzevski, Tomislav [1 ]
Bajt, Mirna [4 ]
Vujic, Goran [1 ]
机构
[1] Univ Hosp Ctr Zagreb, Dept Obstet & Gynecol, Petrova 13, Zagreb 10000, Croatia
[2] Childrens Hosp Zagreb, Zagreb, Croatia
[3] Gen Hosp Zadar, Dept Obstet & Gynecol, Zadar, Croatia
[4] Univ Zagreb, Sch Med, Zagreb, Croatia
关键词
Malignant ovarian germ cell tumors; Fertility-sparing surgery; Reproductive outcome; Adjuvant chemotherapy; CONSERVATIVE SURGERY; STAGE-I; REPRODUCTIVE FUNCTION; CLASSIFICATION; CHEMOTHERAPY; MANAGEMENT; CISPLATIN; BLEOMYCIN; CANCER;
D O I
10.1007/s00404-020-05522-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose To describe a case series of patients with malignant ovarian germ cell tumors (MOGCT) treated exclusively with fertility-sparing surgery (FSS) with or without adjuvant chemotherapy. Methods We retrospectively reviewed the records of 27 patients with MOGCT treated in the Department of Obstetrics and Gynecology, University Hospital Center Zagreb, Croatia, between January 2009 and July 2019. Results The median age at diagnosis was 22 years, and the main symptom was abdominal distension (57.0%). The most prevalent histological subtype was immature teratoma (n = 13, 48.1%). Twenty-three patients (85.2%) had laparotomy and 4 (14.8%) had laparoscopy, without conversions. Lymphadenectomy was performed in 16 (59.3%) patients, with 184 removed lymph nodes, and omentectomy was performed in 19 (70.4%) patients. The rate of chemotherapy administration was 81.5%. The follow-up length ranged between 6.30 and 115.1 months (median: 49.60 months). No patient experienced tumor recurrence. The rate of complete gross resection was 100%. At the time of analysis, all patients were alive and disease free. Fifty percent of patients who actively tried to conceive after FSS became pregnant, with 12 deliveries. Conclusion This study suggests that FSS is a safe treatment option for MOGCT, regardless of tumor stage and histological type.
引用
收藏
页码:1227 / 1233
页数:7
相关论文
共 50 条
  • [31] Fertility management for malignant ovarian germ cell tumors patients
    Di Tucci, Chiara
    Casorelli, Assunta
    Morrocchi, Elisa
    Palaia, Innocenza
    Muzii, Ludovico
    Panici, Pierluigi Benedetti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 : 34 - 42
  • [32] A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors
    Zhang, Ning
    Chen, Ruifang
    Hua, Keqin
    Zhang, Ying
    JOURNAL OF OVARIAN RESEARCH, 2017, 10
  • [33] A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors
    Ning Zhang
    Ruifang Chen
    Keqin Hua
    Ying Zhang
    Journal of Ovarian Research, 10
  • [34] Laparoscopic-Assisted Fertility-Sparing Surgery for Growing Teratoma Syndrome of the Ovary: Experience From a Tertiary Center
    Wang, Dan
    Jia, Congwei
    Wang, Ruojiao
    He, Yonglan
    Zhang, Xinyue
    Yang, Jiaxin
    Xiang, Yang
    Wang, Tao
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2024, 31 (11) : 966 - 972
  • [35] SURGICAL-MANAGEMENT OF MALIGNANT OVARIAN GERM-CELL TUMORS - 10 YEARS EXPERIENCE OF 129 PATIENTS
    PECCATORI, F
    BONAZZI, C
    CHIARI, S
    LANDONI, F
    COLOMBO, N
    MANGIONI, C
    OBSTETRICS AND GYNECOLOGY, 1995, 86 (03): : 367 - 372
  • [36] Feasibility of Fertility-Sparing Surgery After Neoadjuvant Chemotherapy for Advanced Malignant Germ Cell Tumor of the Ovary
    J. S. Anjana
    S. Suchetha
    P. Rema
    J. Siva Ranjith
    Dhanya Dinesh
    Francis V. James
    Aswin Kumar
    K. M. Jagathnath Krishna
    Indian Journal of Gynecologic Oncology, 2022, 20
  • [37] Feasibility of Fertility-Sparing Surgery After Neoadjuvant Chemotherapy for Advanced Malignant Germ Cell Tumor of the Ovary
    Anjana, J. S.
    Suchetha, S.
    Rema, P.
    Ranjith, J. Siva
    Dinesh, Dhanya
    James, Francis, V
    Kumar, Aswin
    Krishna, K. M. Jagathnath
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 20 (04)
  • [38] Hematologic Malignancies Associated With Mediastinal Germ Cell Tumors: 10 Years' Experience at Thailand's National Pediatric Tertiary Referral Center
    Sowithayasakul, Panjarat
    Sinlapamongkolkul, Phakatip
    Treetipsatit, Jitsupa
    Vathana, Nassawee
    Narkbunnam, Nattee
    Sanpakit, Kleebsabai
    Buaboonnam, Jassada
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (06) : 450 - 455
  • [39] Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours
    Gadducci, Angiolo
    Lanfredini, Nora
    Tana, Roberta
    GYNECOLOGICAL ENDOCRINOLOGY, 2014, 30 (07) : 467 - 471
  • [40] ANTI-MULLERIAN HORMONE AS A MARKER OF OVARIAN RESERVE IN PATIENTS WITH GERM CELL OVARIAN TUMORS WHO HAVE UNDERGONE FERTILITY-SPARING TREATMENT
    Sigismondi, C.
    Ottolina, J.
    Rabaiotti, E.
    Vigano, R.
    De Marzi, P.
    Mangili, G.
    Candiani, M.
    Papaleo, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)